Gefitinib: Phase II and III Results in Advanced Non-Small Cell Lung Cancer

Karen Kelly, Steven Averbuch

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalSeminars in Oncology
Issue number1 SUPPL. 1
StatePublished - Feb 2004
Externally publishedYes

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Gefitinib: Phase II and III Results in Advanced Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this